Methotrexate (MTX) and cytarabine have been widely used for the treatment of acute leukemias and lymphomas for over 30 years. However, the optimal schedule of this combination is yet to be determined and a variety of schedules of the combination has been used. We studied the cytotoxic effects of MTX and cytarabine in combination against human leukemia cell lines at various schedules in vitro. The effects of the combinations at the concentration of drug that produced 80% cell growth inhibition (IC 80 ) were analyzed using the isobologram method of Steel and Peckham. Simultaneous exposure to MTX and cytarabine for 3 days produced antagonistic effects in human T cell leukemia, MOLT-3 and CCRF-CEM, B cell leukemia, BALL-1, Burkitt's lymphoma, Daudi, promyelocytic leukemia, HL-60 and Philadelphia chromosome-positive leukemia, K-562 cells. Simultaneous exposure to MTX and cytarabine for 24 h produced antagonistic effects, sequential exposure to MTX for 24 h followed by cytarabine for 24 h produced synergistic effects, and the reverse sequence produced additive effects in both CCRF-CEM and HL-60 cells. Sequential exposure to MTX for 24 h followed by cytarabine for 3 days also produced synergistic effects in MOLT-3 cells. Cell cycle analysis supported these observations. Our findings suggest that the simultaneous administration of MTX and cytarabine is not appropriate and the sequential administration of MTX followed by cytarabine may be the optimal schedule of this combination.
Introduction
Methotrexate (MTX) and cytarabine have been widely used for the treatment of acute leukemias and lymphomas for over 30 years. However, the optimal schedule of the combination of MTX and cytarabine is yet to be determined. In regimens including MTX and cytarabine, the schedules of administering MTX and cytarabine have been variable. In general, MTX and cytarabine have been used separately. [1] [2] [3] However, in some regimens, MTX and cytarabine have been administered simultaneously (on the same day), eg as triple combinations for central nervous system (CNS) prophylaxis and CNS leukemia, 4, 5 PROMACE-cytaBOM 6, 7 and AMOPLACE 8 for non-Hodgkin's lymphoma, POG8602 and EORTC58881 for pediatric acute lymphoblastic leukemia (ALL) 9, 10 and sequentially on different days, eg Hyper-CVAD for ALL and CHOD/BVAM for lymphoma. [11] [12] [13] [14] Experimental findings for the combination of MTX and cytarabine, most of which were obtained more than 20 years ago, are variable (Table 1 ). In both in vitro and in vivo experiments, the simultaneous exposure to MTX and cytarabine produced conflicting results: [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] istic effects. 16, 18, 23 The sequential exposure to both agents also produced conflicting results. 15, 17, 18, 20, 21, 23, 24 No well-designed clinical randomized trial of this combination has been available.
In experimental combination studies, a great deal of confusion has arisen because dose-response curves or survivals for anticancer agents are variable and different investigators have disagreed as to what constitutes an 'expected' level of effect when two agents are combined. 25, 26 Although doseresponse curves and survivals of anticancer agents are important factors in the analysis of the effects of drug combinations, many studies lack full dose-response data for each drug, either alone or in combination.
In in vivo studies, synergism (therapeutic synergism) is often defined as if the combinations produce a better response than either drug alone, with acceptable toxicity. This definition is a quite different concept from true synergism, which means that the effect of combination is more than expected, when combined. 27 In in vitro studies, the classical isobologram 28 and fractional product method 29 have often been used, which assume linear-dose response curves for each drug and combinations, which is seldom the case. The median effect method 30 requires rigid sigmoid dose-response curves, based upon the Michaels-Menten and Hill model. However, cytotoxic mechanisms of anticancer agents are multifactorial and dose-response curves are often not sigmoid and regression analyses are difficult or forced. We use the isobologram method of Steel and Peckham, 31 because this method can be used to calculate additive interaction of most combinations, irrespective of the shapes of the dose-response curves of the agents and whether they have independent or overlapping damage.
To clarify the optimal schedule of the combination of MTX and cytarabine, we studied the effects of simultaneous and sequential exposure to MTX and cytarabine in human leukemia cell lines in vitro using the isobologram of Steel and Peckham. The present findings clearly demonstrated marked antagonistic effects in simultaneous exposure to MTX and cytarabine and marked synergistic effects in sequential exposure to MTX followed by cytarabine, suggesting that the optimal schedule of this combination may be the sequential administration of MTX followed by cytarabine, but not the simultaneous administration of these agents.
Materials and methods

Cell lines
Experiments were conducted with the T cell ALL lines MOLT-3 and CCRF-CEM, the B cell ALL line BALL-1, 32 Burkitt's lymphoma line Daudi, the Philadelphia chromosome-positive leukemia line K-562, and the acute promyelocytic leukemia line HL-60. CCRF-CEM, HL-60, K-562, MOLT-3 cells were Leukemia obtained from the Health Science Research Resources Bank (Osaka, Japan). BALL-1 and Daudi cells were obtained from RIKEN Cell Bank (Tsukuba, Japan). All cell lines were cultured in RPMI1640 medium (GIBCO, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal calf serum (GIBCO), 50 units/ml penicillin and 5 g/ml streptomycin at 37°C in a humidified chamber with 5% CO 2 in air.
Drugs
MTX and cytarabine were obtained from Lederle Japan (Tokyo, Japan), and Nihon Shinyaku (Tokyo, Japan), respectively. Drugs were dissolved in and diluted with culture medium.
Cell growth inhibition by the combination of MTX and cytarabine
Eight plates were prepared for one combined drug test.
Protocol 1: simultaneous exposure to MTX and cytarabine for 3 days:
All six leukemia cell lines were used for the experiments. Logarithmically growing cells were harvested, resuspended in fresh medium (0.5-1 × 10 5 cells/ml) and plated in 96-well plates (Falcon, Oxnard, CA, USA) (100 l cell suspension per well) and all plates had a control column containing medium alone. Drug solutions of MTX and cytarabine at different concentrations (50 l each) were then added to individual wells. Drug concentrations used were those obtained clinically and required for making dose-response curves, up to IC 90 , appropriately. The plates were then incubated for 3 days.
Protocol 2: simultaneous and sequential exposure to MTX and cytarabine for 24 h:
CCRF-CEM and HL-60 cells were used for the experiments. For the simultaneous exposure to MTX and cytarabine, cell suspensions (100 l) and solutions of MTX (50 l) and cytarabine (50 l) at different concentrations were added to individual wells. The plates were then incubated for 24 h. The cells were then washed twice with medium, and then fresh medium (200 l) was added. The plates were incubated again under the same conditions for 3 days. For the sequential exposure to these agents, cell solutions (100 l), solutions of MTX (or cytarabine) (50 l) and medium (50 l) were added to individual wells. The plates were then incubated for 24 h. The cells were then washed twice with medium, and then fresh medium (150 l) and solutions of cytarabine (or MTX) (50 l) were added. The plates were incubated again under the same conditions for 24 h. After that the cells were washed twice, fresh medium was added (200 l) and the cells were incubated again for 2 days.
Protocol 3: sequential exposure to MTX for 24 h followed by cytarabine for 3 days:
MOLT-3 cells were used for the experiments. Cell suspensions (100 l), solutions of MTX (50 l) and medium (50 l) were added to individual wells. The plates were then incubated for 24 h. The cells were then washed twice with medium, and then fresh medium (150 l) and solutions of cytarabine (50 l) were added. The plates were incubated again under the same conditions for 3 days.
MTT assay
Cell growth inhibition was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 33 Fifty microliters of MTT (1 mg/ml) was added to each well. Following incubation for 4 h at 37°C, culture plates were centrifuged at low speed and the supernatant was removed. Dimethyl sulfoxide (150 l) was then added and the plates were shaken to solubilize the MTT-formazan product. Absorbance at 570 nm was measured with a Titertek multiscan. For the background control, control (no drug), each drug, or drug combinations, the four intermediate data among the eight data were used for the analysis, and the two highest and the two lowest data were discarded. We established a linear relation between the MTT assay and cell number within the range of the experiments shown.
Isobologram
Dose-response interactions between MTX and cytarabine at the point of IC 80 were evaluated using the isobologram method of Steel and Peckham. 31 The theoretical basis of the isobologram method and the procedure for making the isobologram has been described in detail.
34, 35 Based on the doseresponse curves of MTX and cytarabine, three isoeffect curves were constructed ( Figure 1 ). If the agents were acting additively by independent mechanisms, combined data points would lie near the mode I line (hetero-addition). If the agents were acting additively by similar mechanisms, the combined data points would lie near the mode II lines (iso-addition). When the data points of a drug combination fell within the area surrounded by the three lines (envelope of additivity), the combination was regarded as additive. The envelope of additivity should not be considered as a reliable definition of additivity. The expression of uncertainty is an important concept of the isobologram method of Steel and Peckham. 31 We used this envelope not only to evaluate combinations in which cells were simultaneously exposed to MTX and cytarabine, but also to evaluate combinations in which the cells were sequentially exposed to both agents, since the second agent under the present experimental conditions could modulate the cytotoxicity of the first agent.
When the data points fell to the left of the envelope (ie the combined effect was caused by lower doses of the two agents than predicted), we regarded the drug combination as having a supra-additive effect (synergism). When the points fell to the right of the envelope (ie the combined effect was caused by higher doses of the two agents than predicted), but within the square or on the line of the square, we regarded the combination as having a sub-additive effect, ie the combination was superior or equal to a single agent but was less than additive. When the data points were outside the square, the combination was regarded as having a protective effect, ie the combination was inferior in cytotoxic action to a single agent. Both sub-additive and protective interactions were regarded as antagonistic effects.
Statistical analysis
Statistical analysis was performed as described previously. 36 If the mean value of the observed data was equal to or smaller than that of the predicted maximum values and equal to or larger than that of the predicted minimum values, the combination was regarded as having an additive effect. If the mean value of the observed data was smaller than that of the predicted minimum values or larger than that of the predicted maximum values, the combinations were considered to have a synergistic or antagonistic effect, respectively. To determine whether the condition of synergism (or antagonism) truly existed, the Wilcoxon signed-rank test was performed for comparing the observed data with the predicted minimum (or maximum) values for an additive effect, which were closest to the observed data (ie the data on the boundary (mode I or mode II lines) between the additive area and supra-additive area (or sub-additive and protective areas). Probability (P) values р0.05 were considered significant. Combinations with P Ͼ 0.05 were regarded as having an additive to synergistic (or additive to antagonistic) effect. All statistical analyses were performed using the StatView 4.01 software program (Abacus Concepts, Berkeley, CA, USA).
Cell cycle analysis by flow cytometry
Cell cycle analysis was performed using MOLT-3 cells. Cells were cultured in the presence of either no drug, 50 nM MTX alone, 50 nM cytarabine alone or 50 nM MTX and 50 nM cytarabine for 24 h. Cells were also treated with or without 50 nM MTX for 24 h, washed, and cultured with or without 50 nM cytarabine for a further 24 h. Then, the cells were stained with propidium iodide in preparation for flow cytometry with the FACScan/CellFIT system (Becton Dickinson, San Jose, CA,USA). DNA histogram was obtained by analyzing 25 000 cells with the ModFIT program (Becton Dickinson). 37 Figure 2 shows the dose-response curves for MTX in combination with cytarabine for the MOLT-3 cells in simultaneous exposure to MTX and cytarabine for 3 days (a) and sequential exposure to MTX for 24 h followed by cytarabine for 3 days (b). Each isobologram was generated based on such doseresponse curves.
Leukemia
Results
Isobologram analysis
Protocol 1: simultaneous exposure to MTX and cytarabine for 3 days: Figure 3 shows the isobolograms for MOLT-3 (a), CCRF-CEM (b), BALL-1 (c), Daudi (d), K-562 (e), and HL-60 (f) cells, respectively. For all cell lines tested, all or most data points were in the areas of subadditivity and protection. The mean values of the observed data were larger than those of the predicted maximum additive values ( Table 2 ). The observed data and the predicted maximum values were compared by Wilcoxon signed-rank test. The observed data were significantly larger than the predicted maximum values (Table  2) , indicating antagonistic effects of simultaneous exposure to these two agents for all these cell lines.
Protocol 2: simultaneous and sequential exposure to MTX and cytarabine for 24 h:
Since simultaneous exposure to MTX and cytarabine for 3 days produced antagonistic effects in all six leukemia cell lines, cytotoxic effects of simultaneous and sequential exposure to MTX and cytarabine for 24 h were studied using CCRF-CEM and HL-60 cells. Figure 4a -f shows the isobolograms for CCRF-CEM (a-c) and HL-60 (d-f) cells, respectively. In simultaneous exposure to MTX and cytarabine for 24 h (a, d), all or most data points fell in the areas of subadditivity and protection. The observed data were significantly larger than the predicted maximum values (Table 1) , indicating antagonistic effects for CCRF-CEM and HL-60 cells. In sequential exposure to MTX for 24 h followed by cytarabine for 24 h (b, e), most data points fell in the area of supraadditiv-
Figure 2
Dose-response curves MTX in combination with cytarabine in MOLT-3 cells. Cells were exposed to these two drugs simultaneously for 3 days (a), and sequentially MTX for 24 h followed by cytarabine for 3 days (b). The cell number was measured using the MTT assay and was plotted as a percentage of the control (cells not exposed to drugs). The concentrations of MTX are shown on the abscissa. The concentrations of cytarabine were 0 (᭺), 10 (b), 20 (), 50 (̆) and 100 (̄) nM. Data are mean values for three independent experiments. Each point represents the mean value for at least three independent experiments; s.e. were less than 25% and were omitted.
Figure 3
Isobolograms of simultaneous exposure to MTX and cytarabine for 3 days for the MOLT-3 (a), CCRF-CEM (b), BALL-1 (c), Daudi (d), K-562 (e) and HL-60 (f) cells. Data are presented as means ± s.e. for at least three independent experiments. The data points marked * indicate that s.e. were greater than 30%. The data points for the combination fell mainly in the areas of subadditivity and protection against all these cell lines, indicating antagonism.. Even if s.e. of data points in the area of protection were greater than 30%, the error bars of data points did not cross the envelope.
Table 2
Mean values of observed data, predicted minimum and predicted maximum values of methotrexate (MTX) in combination with cytarabine (ara-C)
Schedule
Cell ity for both cell lines. The observed data were significantly smaller than the predicted minimum values (Table 2) , indicating synergistic effects. In sequential exposure to cytarabine followed by MTX (c, f), all data points fell within the envelope of additivity for both cell lines. The observed data were larger than the predicted minimum values and smaller than the predicted maximum values (Table 2) , indicating additive effects.
Protocol 3: sequential exposure to MTX for 24 hours followed by cytarabine for 72 h:
As MTX is usually administered for 1 day and cytarabine is administered for several days, we further studied the cytotoxic effects of sequential exposure to MTX for 24 h followed by cytarabine for 3 days using MOLT-3 cells. Figure 4g shows the isobologram for MOLT-3 cells of this schedule. All data points fell in the area of supraadditivity.
Figure 4
Isobolograms of simultaneous exposure to MTA and cytarabine for 24 h (a, d), sequential exposure to MTX for 24 h followed by cytarabine for 24 h (b, e) and the reverse sequence (c, f) for the CCRF-CEM (a-c), and HL-60 cells (d-f) and an isobologram of sequential exposure to MTX for 24 h followed by cytarabine for 3 days for the MOLT-3 cells (g). Data are presented as means ± s.e. for at least three independent experiments. The error bars s.e. from the mean values. The data points marked * indicate that s.e. were greater than 30%. In simultaneous exposure to MTX and cytarabine, all or most data points fell in the areas of subadditivity and protection (a, d), suggesting antagonism. Even if s.e. of data points in the area of protection were greater than 30%, the error bars of data points did not cross the envelope. In sequential exposure to MTX followed by cytarabine (b, e, g), all or most data points fell in the area of supraadditivity, suggesting synergistic effects. In the reverse sequence (c, f), all data points fell within the envelope of additivity, suggesting additive effects.
The observed data were significantly smaller than the predicted minimum values (Table 2) , indicating synergistic effects.
Cell cycle cytometric analysis
Cell cycle analysis revealed that, when used alone, MTX and cytarabine accumulated MOLT-3 cells in the G1 to early S phases and the late S to early G2 phases, respectively ( Figure  5b and c) . Simultaneous exposure of MOLT-3 cells to MTX and cytarabine for 24 h resulted in G1 arrest without a significant increase in the sub G1 fraction (Figure 5b and c) . In contrast, sequential treatment of the cells with MTX for 24 h Leukemia followed by cytarabine for 24 h induced a marked increase in apoptotic cells (Figure 5h) . The remaining cells showed cell cycle arrest in the G1 to S phases after the sequential addition.
Discussion
In the present study, we demonstrated that cytotoxic effects of MTX in combination with cytarabine are definitely scheduledependent. Simultaneous exposure to MTX and cytarabine for 3 days or 24 h produced antagonistic effects. Sequential exposure to MTX for 24 h followed by cytarabine for 24 h produced synergistic effects, while the reverse sequence produced additive effects, suggesting that the optimal schedule of this combination is MTX followed by cytarabine. Since MTX is usually administered for 1 day and cytarabine is administered for several days, we further studied the cytotoxic effects of sequential exposure to MTX for 24 h followed by cytarabine for 3 days. This schedule also showed synergistic effects.
In general, the definition of synergism or antagonism of isobologram of Steel and Peckham is stricter that that of other methods. The present findings support the observations of Burchenal et al, 15 Grindey et al, 16 Hoovis et al 17 and Tanizawa et al, 24 and suggest that the sequential administration of MTX followed by cytarabine would be the optimal schedule of this combination and simultaneous administration would be inappropriate.
In the present study, the data points on the isobolograms of simultaneous exposure to MTX and cytarabine for 3 days (Figure 3a-f) and for 24 h (Figure 4a, d ) fell in the areas of subadditivity and protection. The observed data points for the MOLT-3 and CCRF-CEM cells (Figure 3a, b) and for the CCRF-CEM and HL-60 cell (Figure 4a, d) were greater than 1.0 ( Table 1 ), indicating that each drug alone is more cytotoxic than the simultaneous combination. The observed data points for four other cell lines (Figure 3c-f) were also close to 1.0 ( Table 1 ), suggesting that the combination of both agents was almost equally cytotoxic to each drug alone.
The mechanism underlying the antagonistic or synergistic interaction that occurs with simultaneous exposure to MTX and cytarabine is unclear. The 'protective effects' of the combination in simultaneous exposure means that the cytotoxic effects of MTX and cytarabine are inhibited by each other. Both agents are definitely cell cycle-dependent. MTX has major cytotoxic effects on cells in the S phase and accumulates in cells in the G1 to early S phase, 38 while cytarabine has major cytotoxic effects in the S phase and accumulates in cells in the late S and early G2 phases 39 ( Figure 5 ). Thus, one agent might reduce the cytotoxicity of the other agent by preventing cells from entering the specific phase in which the cells are most sensitive to the other agent.
Sequential exposure to MTX followed by cytarabine showed synergistic effects. The synchronization of the population in the early S phase by MTX would prime cells for increased incorporation of cytarabine. Since cytarabine is a deoxycytidine analog, the potentiation of its activity may also have resulted from depletion of dCTP after MTX treatment. MTX, an inhibitor of dihydrofolate reductase, simultaneously reduced deoxynucleotide pools. 40 In cells treated with MTX followed by cytarabine, depletion of dCTP by MTX may have increased deoxycytidine kinase activity. The sequential treatment with MTX then cytarabine has been observed to augment the generation of ara-CTP and the formation of DNA strand breaks. 17, 21, 24, 41 It must be noted that there are a number of difficulties in translating results from in vitro to clinical therapy. First, the biochemistry of the cells may be quite different although the mechanisms of cytotoxicity are generally thought to be similar. Second, standard culture medium contains high concentrations of folate instead of 5-methyltetrahydrofolate (major folate in human plasma). Third, pharmacokinetic, cell kinetics and other obvious parameters may differ significantly between the two. Fourth, the toxic effects of the combination can not be measured in an in vitro system.
In clinical oncology, the simultaneous administration of MTX and cytarabine (and gluco-corticosteroid) (triple combination) has been widely used for the treatment of CNS leukemia and CNS prophylaxis. Although a variety of clinical studies have been performed over the past three decades, progress has been slow and the role and optimal treatment for CNS prophylaxis and CNS leukemia remain controversial. 4, 5 Since cranial radiation is associated with significant neurological disturbances, intrathecal chemotherapy has come to be preferred. The intrathecal therapy of MTX and cytarabine has been preferred to that of MTX alone, since many oncologists think the combination better than monotherapy. However, no randomized studies comparing the combination of MTX and cytarabine and MTX alone have been reported. CNS prophylaxis using intrathecal MTX and cytarabine was observed to produce more neuro-psychogenic toxicity than cranial radiation and intrathecal MTX. 42 In recent brief-duration highintensity chemotherapy for patients with small noncleavedcell lymphoma or L3 ALL, the simultaneous intravenous administration of high-dose methotrexate and intermediatedose cytarabine, simultaneous intrathecal methotrexate and cytarabine and cranial irradiation were associated with an excessive rate of intolerable and sometimes irreversible neurologic changes. 43 These clinical observations suggest the possibility that the combination produces equivalent or decreased anti-leukemic activity with increased toxicity. It is important to have a randomized trial comparing the effects and neurologic toxicities of MTX plus cytarabine and MTX alone against CNS leukemia and CNS prophylaxis.
Although MTX is a main drug used for CNS prophylaxis, Leukemia some patients relapse with CNS leukemia. Thus, the combination of MTX with other agents is a logical approach to improve antitumor response. The findings of our study suggest that cytarabine appears inadequate for simultaneous administration with MTX. If both MTX and cytarabine are used for CNS leukemia and CNS prophylaxis, it may be better to administer these agents sequentially or quite separately. MTX and cytarabine are cell cycle-specific with short-half lives within the CSF. 44, 45 As a result, the exposure of tumor cells in the CSF to the cytotoxic drug levels may be insufficient. Recently, a sustained-release formulating cytarabine capable (Depo-Cyto) of maintaining a cytotoxic concentration in the CSF for more than 14 days after a single injection has been incorporated into clinical use. 46 The present findings suggest that the intrathecal use of MTX within 14 days after Depo-Cyto may be inappropriate. If MTX is combined with Depo-Cyto, MTX followed by Depo-Cyto (for example MTX day 1 and Depo-Cyto day 4) would be the optimum.
The third-generation regimen for non-Hodgkin's lymphoma 'PROMACE-cytaBOM' and its modification 'intensive PRO-MACE-cytaBOM' 6, 7 are also used for the simultaneous administration of MTX and cytarabine. This dose-intensive regimen, at first, reported an improved response rate and survival compared with standard 'CHOP' therapy. However, a large randomized trial did not show any significant difference between them. 47 The inadequate schedule of the combination of MTX and cytarabine might partially contribute to the results.
The POG protocol 8602 for ALL randomized treatment groups for consolidation treatment was as follows: one receiving six MTX (24 h infusion) alone (regimen A); the other six MTX overlapping cytarabine (24 h infusion began at 12 h of MTX infusion)(regimen C). 9 During consolidation treatment, regimen C had significantly more bacterial infection. There was no significant advantage of regimen C in terms of improvement in event-free survival. The results of POG8602 suggest that overlapping administration of MTX and cytarabine was not the optimum. In this regimen, the administration of MTX and cytarabine resulted in markedly lower RBC MTX levels when compared with the levels of patients with MTX alone. 48 Patients whose MTX levels were extremely low had an adverse prognosis. Very recently, the results of the EORTC 58881 study were reported, which was designed to test in a prospective randomized trial the value of high-dose cytarabine simultaneously added to high-dose MTX after completion of the induction-consolidation phase in ALL and lymphoblastic lymphoma in children treated with a Berlin-FrankfurtMunster (BFM)-based regimen. 10 The addition of high-dose cytarabine failed to decrease the incidence of CNS relapse and to improve the overall disease-free survival. The antagonistic interaction between MTX and cytarabine might contribute to the negative results of POG8602 and EORTC58881 for this combination.
Although MTX followed by cytarabine produced synergistic effects, the clinical application of this schedule has rarely been employed. [10] [11] [12] [13] For pediatric patients with advanced B cell malignancies, a treatment plan which consists of four courses of fractionated cyclophosphamide administered with doxorubicin and vincristine alternating with sequential highdose MTX and cytarabine showed high response rates and increased survival rate. 12 For adult patients with ALL, a treatment which consists of eight cycles of HyperCVAD plus highdose MTX (1000 mg/m 2 on day 1) followed by high-dose cytarabine (3 g/m 2 × 4 on days 2 and 3) showed 39% and 38% of the estimated 5-year survival and 5-year CR rates, respectively. 13 Since the sequential administration of MTX followed by cytarabine is only part of the clinical regimens, it appears difficult to evaluate the efficacy of this sequence. In both regimens, however, this sequence might contribute to the good results.
In conclusion, simultaneous exposure to MTX and cytarabine produced marked antagonistic effects, while sequential exposure to MTX followed by cytarabine produced synergistic effects against the human leukemia cell lines tested. Although no in vitro model is absolutely predictive for clinical activity, the present findings suggest that, in the clinical setting, the simultaneous administration of MTX and cytarabine is inadequate and the sequential administration of MTX followed by cytarabine is appropriate for antitumor effects if MTX and cytarabine are combined.
